TRANSDERMAL DRUG DELIVERY PATCHES:  A REVIEW by Prabhakar, D et al.
Prabhakar et al                  Journal of Drug Delivery & Therapeutics; 2013, 3(4), 213-221 213 
© 2011, JDDT. All Rights Reserved                                                      ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
Available online at http://jddtonline.info 
REVIEW ARTICLE 
TRANSDERMAL DRUG DELIVERY PATCHES:  A REVIEW 
*
D. Prabhakar
1
, J. Sreekanth
2
, K.N. Jayaveera
3 
1
Department of Pharmaceutics, Trinity College of Pharmaceutical Sciences, Karimnagar, A.P, India 
2
MSN Laboratories Hyderabad, A.P, India 
3
Jawaharlal Nehru Technological University, Anantapur-Dist, A.P, India 
*Corresponding Author’s Mail address: prabhakardontha@gmail.com, Mobile. No +91 9849927338 
 
 
 
 
 
 
 
 
 
INTRODUCTION: 
Drugs administered in the conventional dosage forms 
usually produce large range in fluctuations in plasma drug 
concentrations leading to undesirable toxicity or poor 
effectiveness. These factors as well as other factors such 
as repetitive dosing and unpredictable absorption, led to 
the concept of the controlled drug delivery system or 
therapeutic system. A dosage form that releases one or 
more drugs continuously in a predetermined pattern for a 
fixed period of time, either systemically or to a specified 
target organ is a controlled drug delivery system. The 
primary objectives of controlled drug delivery are to 
ensure safety and to improve efficacy of drugs as well as 
patient compliance. This is achieved by better control of 
plasma drug levels and less frequent dosing. Transdermal 
therapeutic systems are defined as self-contained discrete 
dosage forms which, when applied to the intact skin, 
deliver the drug(s), through the skin, at controlled rate to 
the systemic circulation
1, 2
.
  
The first Transdermal drug delivery (TDD) system, 
Transderm-Scop developed in 1980, contained the drug 
Scopolamine for treatment of motion sickness. The 
Transdermal device is a membrane-moderated system. 
The membrane in this system is a microporous 
polypropylene film. The drug reservoir is a solution of the 
drug in a mixture of mineral oil and polyisobutylene. This 
study release is maintained over a three-day period
3
.  
Advantages:  
There are many advantages associated with Transdermal 
drug delivery systems
4
, 5. 
 The drugs by pass the hepatic and pre systemic 
metabolism thereby increasing bioavailability. 
 Risks and inconveniences of IV therapy are avoided. 
 Reduced dose frequency and predictable sustained and 
extended duration of action. 
 Easy termination of drug therapy. 
 It gives greater patient compliance due to elimination 
of multiple dosing intervals. 
 Enhanced therapeutic efficiency by avoiding the peaks 
and troughs in systemic drug levels associated with 
conventional delivery. 
 Self –administration is possible. 
PHYSIOLOGY OF THE SKIN: 
Skin of an average adult body covers a surface of 
approximately 2 m 
2 
and receives about one-third of the 
blood circulating through the body. Skin contains (Figure 
1) an uppermost layer, epidermis which has 
morphologically distinct regions; basal layer, spiny layer, 
stratum granulosum and upper most stratum corneum, it 
consists of highly cornified (dead) cells embedded in a 
continuous matrix of lipid membranous sheets. These 
extracellular membranes are unique in their compositions 
and are composed of ceramides, cholesterol and free fatty 
acids. The human skin surface is known to contain, on an 
average, 10-70 hair follicles and 200-250 sweat ducts on 
every square centimeters of the skin area. It is one of the 
most readily accessible organs of the human 
body5, 6
. 
 
ABSTRACT: 
For thousands of years, human civilizations have applied substances to the skin as cosmetic and medicinal agents. However, it 
was not until the twentieth century that the skin came to be used as a drug delivery route. In fact, Merriam Webster dates the 
word “transdermal” to 1944 highlighting that it is a relatively recent concept in medical and pharmaceutical practice. 
Transdermal drugs are self‐contained, discrete dosage form. Drug delivery through the skin to achieve a systemic effect 
without producing any fluctuations in plasma concentration of the drug.  Topical administration of therapeutic agents offers 
many advantages over conventional oral and invasive methods of drug delivery.  And also provide controlled release of the 
drug for extended period of the time. This review article covers brief outline advantages, skin pathways for transdermal drug 
delivery systems (TDDS), various components of transdermal patch, and approaches for preparation of transdermal patches, 
evaluation of transdermal system, general clinical considerations in the use of tdds and limitation of tdds. 
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Figure 1: Anatomical and physiological Structure of skin 
SKIN PATHWAYS FOR TRANSDERMAL DRUG 
DELIVERY SYSTEMS:  
When drugs are applied on the skin surface, penetration 
into and through the skin can occur via various routes. 
Drugs penetrate either via the stratum corneum 
(transepidermal) or via the appendages (transappendageal) 
(Figure 2). During penetration through the stratum 
corneum, two possible routes can be distinguished, 
Penetration alternating through the corneocytes and the 
lipid lamellae (transcellular route) and ii) Penetration along 
the tortuous pathway along the lipid lamellae (intercellular 
route).  
 
Figure 2: Possible pathways for permeation of drug across 
the skin barrier 
Generally it is accepted that the predominant route of 
penetration through the stratum corneum is the 
intercellular route. This is mainly caused by the densely 
cross-linked cornified envelope coating the keratinocytes. 
However transcellular transport for small hydrophilic 
molecules such as water cannot completely be excluded. 
The appendage route or shunt route includes either the duct 
of the eccrine sweat glands or the follicular duct. The 
content of the eccrine sweat glands is mainly hydrophilic, 
while the content of the follicular duct is lipophilic. This is 
mainly due to the sebum excreted into the opening of the 
follicular duct. It is generally accepted that due to its large 
surface area, passive skin permeation mainly occurs 
through intact stratum corneum
7-10
.  
BASIC COMPONENETS OF TRANSDERMAL 
DRUG DELIVERY SYSTEMS: 
The components of Transdermal device include
11-13
. 
Polymer matrix 
Drug  
Permeation enhancers   
Other excipients             
Polymer Matrix:                         
The polymer controls the release of the drug from the 
device. The following criteria should be satisfied for a 
polymer to be used in a Transdermal system. Possible 
useful polymers for Transdermal devices are;
 
Table 1: Showing different types of polymers 
Natural Polymers: Synthetic Elastomers Synthetic Polymers 
Cellulose derivatives, 
Zein, Gelatin, Waxes, 
Proteins, Gums, 
Natural rubber, 
Starch. 
Polybutadiene, Hydrin rubber, 
polysiloxane, silicone rubber, 
Nitrile, Acrylonitrile, 
Butylrubber, Styrenebutadiene, 
Neoprene etc. 
Polyethylene, Polypropylene, 
Polyacrylate, Polyamide, 
Polyvinylpyrrolidone, 
Polymethyl methacrylate, 
Epoxy, Polyurea, etc. 
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Drug:  
For successfully developing a Transdermal drug delivery 
system, the drug should be chosen with great care. The 
following are some of the desirable properties of a drug for 
Transdermal delivery.  
Physicochemical Properties: 
 The drug should have a molecular weight less 
than approximately 1000 Daltons. 
 The drug should have affinity for both- lipophilic 
and hydrophilic phases. Extreme partitioning 
characteristics are not conducive to successful drug 
delivery via the skin. 
 The drug should have a low melting point. 
Biological Properties: 
 The drug should be potent with a daily dose of the 
order of a few mg/day. 
 The half life (t1/2) of the drug should be short. 
 The drug must not induce a cutaneous irritation or 
allergic response. 
 Drugs, which degrade in the GI tract or are inactivated 
by hepatic first-pass effect, are suitable candidates for 
Transdermal delivery. 
 Tolerance to the drug must not develop under the near 
zero-order release profile of Transdermal delivery. 
 Drugs, which have to be administered for a long 
period of time or which cause adverse effects to non-
target tissues can also, be formulated for Transdermal 
delivery. 
Permeation Enhancers: 
Permeation enhancers or promoters are agents that have no 
therapeutic properties of their own but can transport the 
sorption of drugs from drug delivery systems onto the 
skin.
11 
The flux, of drugs across the skin can be written as:  
J = D Xdc/dx       
Where D is the diffusion coefficient and is a function of 
size, shape and flexibility of the diffusing molecule as well 
as the membrane resistance; C is the concentration of the 
diffusing species; x is the spatial coordinate. 
Although the solution for J with various boundary 
conditions and membrane heterogeneities can be very 
complex, the basic concepts regarding flux enhancement 
can be found in above equation. The concentration 
gradient is thermodynamic in origin, and the diffusion 
coefficient is related to the size and shape of penetrate and 
the energy required to make a hole for diffusion. Thus 
enhancement of flux across membranes reduces to 
considerations of:  
 Thermodynamics (lattice energies, distribution 
coefficients). 
 Molecular size and shape. 
 Reducing the energy required to make a molecular 
hole in the membrane. 
 Permeation enhancers are hypothesized to affect one 
or more of the layers to achieve skin penetration 
enhancement. A large number of compounds have 
been investigated for their ability to enhance stratum 
corneum permeability. These conveniently classified 
under the following main headings: 
Solvents: These compounds increase penetration possibly 
by 
1). Swelling the polar pathways in the skin. 
2). Fluidization of lipids.  
Examples include water alcohols-methanol and ethanol; 
alkyl methyl sulfoxides-dimethyl sulfoxide, alkyl 
homologs of methyl sulfoxide, dimethyl acetamide and 
dimethyl formamide; pyrrolidones-2-pyrrolidone; 
laurocapram (Azone), miscellaneous solvents-propylene 
glycol, glycerol, silicone fluids, isopropyl palmitate. 
Surfactants: These compounds are proposed to enhance 
polar pathway transport, especially of hydrophilic drugs. 
The ability of a surfactant to alter penetration is a function 
of the head group and the hydrocarbon chain length. These 
compounds are skin irritants, therefore, a balance between 
penetration enhancement and irritation have to be 
considered. Anionic surfactants can penetrate and interact 
strongly with the skin. Once these surfactants have 
penetrated the skin, they can induce large alterations. 
Cationic surfactants are reportedly more irritant than the 
anionic surfactants and they have not been widely studied 
as skin permeation enhancers. Of the three major classes of 
surfactants, the nonionic have long been recognized as 
those with the least potential for irritation and have been 
widely studied.   
Examples of commonly used surfactants are: 
Anionic Surfactants: Dioctyl sulphosuccinate, Sodium 
lauryl sulphate, Decodecylmethyl sulphoxide etc. 
Nonionic Surfactants: Pluronic F127, Pluronic F68, etc. 
Bile Salts : Sodium taurocholate, Sodium deoxycholate, 
Sodium tauroglycocholate. 
Miscellaneous Chemicals: These include urea, a 
hydrating and keratolytic agent; N, N-dimethyl-m-
toluamide; Calcium thioglycolate; Anticholinergic agents. 
Some potential permeation enhancers have recently been 
described but the available data on their effectiveness are 
sparse. These include eucalyptol, di-o-methyl-beta-
cyclodextrin and soyabean casein. 
Other Excipients: 
Adhesives: The fastening of transdermal devices to the 
skin has so far been done by using a pressure sensitive 
adhesive. The pressure sensitive adhesive can be 
positioned on the face of the device or in the back of the 
device and extending peripherally. 
 Both adhesive systems should fulfill the following criteria.
 
 Should not irritate or sensitize the skin or cause an 
imbalance in the normal skin flora. 
 Should adhere to the skin aggressively during the 
dosing interval without its position being disturbed by 
activities such as bathing, exercise etc. 
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 Should be easily removed. 
 Should not leave an unwashable residue on the skin. 
 Should have excellent (intimate) contact with the skin 
at macroscopic and microscopic level. 
Backing Membrane: Backing membranes are flexible and 
they provide a good bond to the drug reservoir, prevent 
drug from leaving the dosage form through the top, and 
accept printing. It is impermeable and protects the product 
during use on the skin e.g. metallic plastic laminate, plastic 
backing with absorbent pad and occlusive base plate a 
(aluminum foil), adhesive foam pad (flexible 
polyurethane) with occlusive base plate (aluminum foil 
disc) etc.   
Release Liner: During storage release liner prevents the 
loss of the drug that has migrated into the adhesive layer 
and contamination. It is therefore regarded as a part of the 
primary packaging material rather than a part of dosage 
form for delivering the drug. The release liner is composed 
of a base layer which may be non‐occlusive (paper fabric) 
or occlusive (polyethylene, polyvinylchloride) and a 
release coating layer made up of silicon or Teflon. Other 
materials used for TDDS release liner include polyester 
foil and metalized laminate. 
DESIGN OF TRANSDERMAL DELIVERY 
SYSTEM: 
The basic components of any transdermal delivery system 
include the drug dissolved or dispersed in an inert polymer 
matrix that provides support and platform for drug release. 
There are two basic designs of the patch system that 
dictate drug release characteristics and patch behavior: 
1) Matrix or Monolithic: The inert polymer matrix binds 
with the drug and controls its release from the device. 
2) Reservoir or Membrane: The polymer matrix does not 
control drug release. Instead, a rate controlling membrane 
present between the drug matrix and the adhesive layer 
provides the rate limiting barrier for drug release from the 
device
14
. 
TECHNOLOGIES FOR DEVELOPING 
TRANSDERMAL DRUG DELIVERY SYSTEMS: 
Several technologies have been successfully developed to 
provide rate control over the release and skin permeation 
of drugs. These technologies can be classified into four 
basic approaches
5, 15
. 
Polymer membrane permeation-controlled TDD 
Systems: 
In this system the drug reservoir is sandwiched between a 
drug-impermeable metallic plastic laminate and a rate-
controlling polymeric membrane. The drug molecules are 
permitted to release only through the rate- controlling 
polymeric membrane. The rate-controlling membrane can 
be either a microporous or nonporous polymeric 
membrane, e.g., ethylene-vinyl acetate copolymer, with 
drug permeability. On the external surface of the 
polymeric membrane a thin layer of drug-compatible, 
hypoallergenic pressure-sensitive adhesive polymer, e.g., 
silicone adhesive, may be applied to provide intimate 
contact of the TDD system with the skin surface (Figure 
3). Ex: Transderm-Nitro system, Transderm-Scop system, 
the Catapres TTS system, the Estraderm system, and the 
Duragesic system.  
Polymer matrix Diffusion-Controlled TDD Systems: 
In this approach the drug reservoir is formed by 
homogeneously dispersing the drug solids in a hydrophilic 
or lipophilic polymer matrix, and the medicated polymer 
formed is then molded into medicated disks with a defined 
surface area and controlled thickness. This drug reservoir- 
containing polymer disc is then mounted onto an occlusive 
base plate in a compartment fabricated from a drug–
impermeable plastic backing. In this system the adhesive 
polymer is applied along the circumference of the patch to 
form a strip of adhesive rim surrounding the medicated 
disc (Figure 4). Ex: Nitro-Dur system and the NTS system. 
 
Figure 3: Transderm-Nitro system 
 
Figure 4: Nitro-Dur Transdermal System 
Drug Reservoir Gradient-Controlled TDD Systems: 
To overcome the non zero-order drug release profiles, 
polymer matrix drug dispersion-type TDD system can be 
modified to have the drug loading level varied in an 
incremental manner, forming a gradient of drug reservoir 
along the diffusional path across the multilaminate 
adhesive layer (Figure 5). Ex: Deponit system.  
Microreservoir Dissolution-Controlled TDD Systems: 
This type of the delivery system can be considered a 
hybrid of the reservoir and matrix dispersion type delivery 
systems. In this approach the drug reservoir is formed by 
first suspending the drug solids in an aqueous solution of a 
water-miscible drug solubilizer, e.g., polyethylene glycol, 
and then homogeneously dispersing the drug suspension, 
with controlled aqueous solubility, in a lipophilic polymer, 
by high shear mechanical force, to form thousands of 
unleachable microscopic drug reservoirs. This 
thermodynamically unstable dispersion is quickly 
stabilized by immediately cross-linking the polymer chain 
in situ, which produces a medicated polymer disc with a 
constant surface area and a fixed thickness (Figure 6).  
Ex: Nitrodisc system. 
Prabhakar et al                  Journal of Drug Delivery & Therapeutics; 2013, 3(4), 213-221 215 
© 2011, JDDT. All Rights Reserved                                                      ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
 
Figure 5: Drug Reservoir Gradient-Controlled TDDS 
 
 
Figure 6: Microreservoir Dissolution-Controlled TDDS 
 
PREPARATION OF TRANSDERMAL PATCHES:  
Transdermal drug delivery patches can be prepared by 
various methods 
Mercury Substrate Method:  
In this method required amount of drug is dissolved in 
predetermined amount of polymer solution along with 
plasticizer. The above solution is to be stirred for some 
time to produce a homogenous dispersion and it is keep 
aside until air bobbles removed completely and then 
poured in to a glass ring which is placed over the mercury 
surface in a glass petri dish. The rate of evaporation of the 
solvent is controlled by placing an inverted funnel over the 
petri dish. The dried films are to be stored in a desiccator
16-
20
. 
Circular Teflon Mould Method:  
Solutions containing polymers in various ratios are used in 
an organic solvent. Calculated amount of drug is dissolved 
in half the quantity of same organic solvent. Plasticizer 
added into drug polymer solution. The total contents are to 
be stirred and then poured into a circular teflon mould. 
And rate of solvent vaporization controlled with placing 
inverted glass funnel on teflon mould. The solvent is 
allowed to evaporate for 24 hrs. The dried films are to be 
stored in a desiccator
21, 22
. 
Glass Substrate Method: 
The polymeric solutions are kept a side for swelling then 
required quantity of plasticizer and drug solution are added 
and stirred for 10 min. Further, it is set-a side for some 
time to exclude any entrapped air and is then poured in a 
clean and dry anumbra petriplate. The rate of solvent 
evaporation is controlled by inverting a glass funnel over 
the petriplate. After over night, the dried films are taken 
out and stored in a desiccator
23-30
. 
By Using IPM Membranes Method:  
In this method drug is dispersed in a mixture of water and 
propylene glycol containing carbomer 940 polymers and 
stirred for 12 hrs in magnetic stirrer. The dispersion is to 
be neutralized and made viscous by the addition of 
triethanolamine. Buffer pH 7.4 can be used in order to 
obtain solution gel, if the drug solubility in aqueous 
solution is very poor. The formed gel will be incorporated 
in the IPM membrane
28, 29
.  
By Using EVAC Membranes Method: 
In order to prepare the target transdermal therapeutic 
system, 1% carbopol reservoir gel, polyethylene (PE), 
ethylene vinyl acetate copolymer (EVAC) membranes can 
be used as rate control membranes. If the drug is not 
soluble in water, propylene glycol is used for the 
preparation of gel. Drug is dissolved in propylene glycol; 
carbopol resin will be added to the above solution and 
neutralized by using 5% w/w sodium hydroxide solution. 
The drug (in gel form) is placed on a sheet of backing 
layer covering the specified area. A rate controlling 
membrane will be placed over the gel and the edges will be 
sealed by heat to obtain a leak proof device
 28, 29
.   
Aluminium Backed Adhesive Film Method:  
Transdermal drug delivery system may produce unstable 
matrices if the loading dose is greater than 10 mg. 
Aluminium backed adhesive film method is a suitable one. 
For preparation of same, chloroform is choice of solvent, 
because most of the drugs as well as adhesive are soluble 
in chloroform. The drug is dissolved in chloroform and 
adhesive material will be added to the drug solution and 
dissolved. A custom made aluminum former is lined with 
aluminum foil and the ends blanked off with tightly fitting 
cork blocks
30, 31
.  
Asymmetric TPX Membrane Method: 
A prototype patch can be fabricated by a heat sealable 
polyester film (type 1009, 3m) with a concave of 1cm 
diameter used as the backing membrane. Drug sample is 
dispensed into the concave membrane, covered by a TPX 
{poly (4-methyl-1-pentene)} asymmetric membrane, and 
sealed by an adhesive
32
. 
GENERAL CLINICAL CONSIDERATIONS IN THE 
USE OF TDDS: 
The patient should be advised of the following general 
guidelines. Rotating of site of application is important to 
allow the skin to regain its normal permeability and to 
prevent skin irritation
15
. 
 TDDS should be applied to clean, dry skin relatively 
free of hair and not oily, inflamed, 
Irritated, broken. Wet or moist skin can accelerate 
drug permeation time. 
 Oily skin can impair the adhesion of patch. If hair is 
present at the site, it should be carefully cut, not wet 
shaved nor should a depilatory agent be used, since 
later can remove stratum corneum and affect the rate 
and extent of drug permeation. 
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 Use of skin lotion should be avoided at the application 
site, because lotions affect the hydration of skin and 
can alter partition coefficient of drug. 
 Patient should not physically alter TDDS, since this 
destroys integrity of the system. 
 The protecting backing should be removed with care 
not to touch fingertips. The TDDS should be pressed 
firmly against skin site with the heel of hand for about 
10 seconds. 
 A TDDS should be placed at a site that will not 
subject it to being rubbed off by clothing or 
movement. TDDS should be left on when showering, 
bathing or swimming.  
 A TDDS should be worn for full period as stated in 
the product’s instructions followed by removal and 
replacement with fresh system.  
 The patient or caregiver should clean the hands after 
applying a TDDS. Patient should not rub eye or touch 
the mouth during handling of the system. 
 If the patient exhibits sensitivity or intolerance to a 
TDDS or if undue skin irritation results, the patient 
should seek reevaluation. 
 Upon removal, a used TDDS should be folded in its 
half with the adhesive layer together so that it cannot 
be reused. The used patch discarded in a manner safe 
to children and pets.  
 Use of transdermal patch It is important to use a 
different application site everyday to avoid skin 
irritation. Suggested rotation is: 
Day 1 – Upper right arm, Day 2 – upper right chest, Day 3 
– Upper left chest, Day 4 – Upper left arm, then repeat 
from Day 1. 
CONDITIONS IN WHICH TRANSDERMAL 
PATCHES ARE USED: 
Transdermal patch is used when: 
 When the patient has intolerable side effects (including 
constipation) and who is unable to take oral medication 
(dysphagia) and is requesting an alternative method of 
drug delivery.  
 Where the pain control might be improved by reliable 
administration. This might be useful in patients with 
cognitive impairment or those who for other reasons 
are not able to self‐medicate with their analgesia33, 34. 
CONDITIONS IN WHICH TRANSDERMAL 
PATCHES ARE NOT USED: 
The use of transdermal patch is not suitable when: 
(1) Cure for acute pain is required. (2) Where rapid dose 
titration is required. (3) Where requirement of dose is 
equal to or less than 30 mg/24 hrs
33, 34
. 
EVALUATION TEST OF TRANSDERMAL PATCH:  
Drug Excipients Interaction Studies: 
The drug and excipients should be compatible to produce a 
stable product, and it is mandatory to detect any possible 
physical and chemical interaction. Interaction studies are 
commonly carried out using thermal analysis, FT-IR 
studies, UV and chromatographic techniques by comparing 
their physiochemical characters such as assay, melting 
endotherms, characteristic wave numbers, and absorption 
maxima etc
32
. 
Drug Content: A specified area of the patch is to be 
dissolved in a suitable solvent in specific volume. Then the 
solution is to be filtered through a filter medium and 
analyse the drug content with the suitable method (UV or 
HPLC technique). Each value represents average of three 
samples
35-37
.  
Weight Uniformity: The prepared patches are to be dried 
at 60°C for 4 hrs before testing. A specified area of patch 
is to be cut in different parts of the patch and weigh in 
digital balance. The average weight and standard deviation 
values are to be calculated from the individual weights
37, 38
.  
Thickness of the Patch: The thickness of the drug loaded 
patch is measured in different points by using a digital 
micrometer and determines the average thickness and 
standard deviation for the same to ensure the thickness of 
the prepared patch
38-41
. 
Flatness Test: Three longitudinal strips are to be cut from 
each film at different portion like one from the center, 
other one from the left side and another one from the right 
side. The length of each strip was measured and the 
variation in length because of non-uniformity in flatness 
was measured by determining percent constriction, with 
0% constriction equivalent to 100% flatness
33
.  
Percentage Moisture Uptake: The weighed films are to 
be kept in desiccators at room temperature for 24 hrs 
containing saturated solution of potassium chloride in 
order to maintain 84% RH. After 24 hrs the films are to be 
reweighed and determine the percentage moisture uptake 
from the below mentioned formula
41, 42
. 
Percentage moisture uptake = [Final weight-Initial weight/ 
initial weight] × 100.   
Moisture Loss: The prepared films are to be weighed 
individually and to be kept in a desiccator containing 
calcium chloride at 40
o
C. After 24 hrs the films are to be 
reweighed and determine the percentage of moisture loss 
from the below formula
43
.
 
 
% Moisture Loss = [Initial wt – Final wt/ Final wt] × 100 
Water Vapor Transmission Rate (WVTR) Studies: 
Glass vials of equal diameter were used as transmission 
cells. These transmission cells were washed thoroughly 
and dried in oven at 100
 o
C for some time. About 1g 
anhydrous calcium chloride was placed in the cells and 
respective polymer film was fixed over brim. The cell 
were accurately weighed and kept in a closed desiccator 
containing saturated solution of potassium chloride to 
maintain a relative humidity of 84%. The cells were taken 
out and weighed after storage. The amount of water vapor 
transmitted was found using following formula
43, 44
. 
Water Vapor Transmission Rate = Final Weight –Initial 
Weight/ Time X Area                 
It is expressed as the number of grams of moisture 
gained/hr/cm.sq. 
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Swellability: The patches of 3.14 cm² was weighed and 
put in a petri dish containing 10 ml of double distilled 
water and were allowed to imbibe. Increase in weight of 
the patch was determined at preset time intervals, until a 
constant weight was observed
45
.  
The degree of swelling (S) was calculated using the 
formula,  
S (%) = W
t 
– W
o
/W
o 
× 100  
Where S is percent swelling  
W
t 
is the weight of patch at time t and W
o 
is the weight of 
patch at time zero.  
Folding Endurance: A strip of specific area is to be cut 
evenly and repeatedly folded at the same place till it broke. 
The number of times the film could be fold at the same 
place without breaking gave the value of the folding 
endurance
 46
.  
Polariscope Examination: This test is to be performed to 
examine the drug crystals from patch by Polariscope. A 
specific surface area of the piece is to be kept on the object 
slide and observe for the drugs crystals to distinguish 
whether the drug is present as crystalline form or 
amorphous form in the patch
21
.   
Percentage Elongation Break Test: The percentage 
elongation break is to be determined by noting the length 
just before the break point, the percentage elongation can 
be determined from the below mentioned formula
47
.  
Elongation percentage = [L1-L2 / L2] × 100 Where, L1 is 
the final length of each strip and L2 is the initial length of 
each strip.  
Tensile Strength: Tensile strength of the film determined 
with universal strength testing machine. The sensitivity of 
the machine was 1 g. It consisted of two load cell grips. 
The lower one is fixed and upper one is movable. The test 
film of size (4 × 1 cm
2)
 is fixed between these cell grips 
and force is gradually applied till the film broke
31
. The 
tensile strength of the film is taken directly from the dial 
reading in kg. Tensile strength is expressed as follows. 
 Tensile strength =Tensile load at break / Cross section 
area 
Probe Tack test: In this test, the tip of a clean probe with 
a defined surface roughness is brought into contact with 
adhesive and when a bond is formed between probe and 
adhesive. The subsequent removal of the probe 
mechanically breaks it. The force required to pull the 
probe away from the adhesive at fixed rate is recorded as 
tack and it is expressed in grams
47
. 
Skin Irritation Study: Skin irritation and sensitization 
testing can be performed on healthy rabbits (average 
weight 1.2 to 1.5 kg). The dorsal surface (50 cm
2
) of the 
rabbit is to be cleaned and remove the hair from the clean 
dorsal surface by shaving and clean the surface by using 
rectified spirit and the representative formulations can be 
applied over the skin. The patch is to be removed after 24 
hrs and the skin is to be observed and classified into 5 
grades on the basis of the severity of skin injury
38
. 
In-vitro drug release studies: The paddle over disc 
method (USP apparatus V) can be employed for 
assessment of the release of the drug from the prepared 
patches. Dry films of known thickness is to be cut into 
definite shape, weighed and fixed over a glass plate with 
an adhesive. The glass plate was then placed in a 500-ml 
of the dissolution medium or phosphate buffer (pH 7.4) 
and the apparatus was equilibrated to 32± 0.5°C. The 
paddle was then set at a distance of 2.5 cm from the glass 
plate and operated at a speed of 50 rpm. Samples (5 ml 
aliquots) can be withdrawn at appropriate time intervals up 
to 24 h and analyzed by UV spectrophotometer or high 
performance liquid chromatography (HPLC). The 
experiment is to be performed in triplicate and the mean 
value can be calculated
48
. 
In-vitro skin permeation studies: An in vitro permeation 
study can be carried out by using diffusion cell. Full 
thickness abdominal skin of male wistar rats weighing 200 
to 250 g. Hair from the abdominal region is to be removed 
carefully by using an electric clipper; the dermal side of 
the skin was thoroughly cleaned with distilled water to 
remove any adhering tissues or blood vessels, equilibrated 
for an hour in diffusion medium or phosphate buffer pH 
7.4 before starting the experiment. 
Diffusion cell filled with diffusion medium and placed on 
a magnetic stirrer with a small magnetic bead for uniform 
distribution of the diffusant. The temperature of the cell 
was maintained at 32 ± 0.5°C using a thermostatically 
controlled heater. The isolated rat skin piece is to be 
mounted between the compartments of the diffusion cell, 
with the epidermis facing upward into the donor 
compartment. Sample volume of definite volume is to be 
removed from the receptor compartment at regular 
intervals and an equal volume of fresh medium is to be 
replaced. Samples are to be filtered through filtering 
medium and can be analyzed spectrophotometrically or 
high performance liquid chromatography (HPLC) 
49-58
. 
Flux can be determined directly as the slope of the curve 
between the steady-state values of the amount of drug 
permeated (mg cm
-2
) vs. time in hours and permeability 
coefficients were deduced by dividing the flux by the 
initial drug load (mg cm
-2
).  
In-vivo studies: In-vivo evaluations are the true depiction 
of the drug performance. The variables which cannot be 
taken into account during in-vitro studies can be fully 
explored during in-vivo studies. In-vivo evaluation of 
TDDS can be carried out using: 
Animal models 
Human volunteers 
Animal models:  
The most common animal species used for evaluating 
transdermal drug delivery system are mouse, hairless rat, 
hairless dog, hairless rhesus monkey, rabbit, guinea pig 
etc. 
Human models: 
The final stage of the development of a transdermal device 
involves collection of pharmacokinetic and 
pharmacodynamic data following application of the patch 
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to human volunteers. Clinical trials have been conducted to 
assess the efficacy, risk involved, side effects, patient 
compliance etc. 
Stability Studies: Stability studies are to be conducted 
according to the ICH guidelines by storing the TDDS 
samples at 40±0.5°C and 75±5% RH for 6 months. The 
samples were withdrawn at 0, 30, 60, 90 and 180 days and 
analyze suitably for the drug content
38.59
.  
LIMITATIONS FOR SELECTION OF TDDS: 
All types of drugs cannot be administered through this 
route; the drug must have some desirable Physico-
Chemical properties.
11 
 Not suitable for drugs that require high plasma levels. 
 Not suitable for drugs that produce skin irritation and 
contact dermatitis. 
 Not suitable for drugs with high molecular weight. 
 Not suitable for drugs that undergo metabolism during 
the passage through the skin. 
 The Transdermal route cannot be employed for a large 
number of drugs, as the skin is a very efficient barrier 
for penetration of drugs. Only with low dose can be 
administered. 
 The barrier nature of the skin changes from one site to 
another in the same person, from person to person and 
also with age. 
CONCLUSION: 
Transdermal drug delivery is a painless, convenient, and 
potentially effective way to deliver regular doses of many 
medications. Wide range of drugs can be delivered 
improved drug uptake Minimal complications and side 
effects low cost and easy to use. Example Ten years ago, 
the nicotine patch had revolutionized smoking cessation; 
patients were being treated with nitroglycerin for angina, 
clonidine for hypertension, scopolamine for motion 
sickness and estradiol for estrogen deficiency, all through 
patches used by over a million patients per year. 
Transdermal delivery of a drug product which is currently 
approved as oral dosage form, allows for the avoidance of 
first pass metabolism. Dermal patches are the most 
common form of transdermal delivery of drugs. However, 
the transdermal technologies have limitations due to the 
relatively impermeable thick of outer stratum corneum 
layer. Researchers are trying to overcome this hurdle of 
poor permeability by physical and chemical means. 
 
REFERENCES: 
1. Panner Selvam R, Anoop Kumar Singh, Sivakumar T, 
Transdermal drug delivery systems for antihypertensive drugs - 
A review, IJPBR, 2010, 1(1), 1-8. 
2. Kakkar A, P and Ajay Gupta, Gelatin Based Transdermal 
Therapeutic System, Indian Drugs, 1991, 29 (7), 308-315. 
3. Chowdary K.P.R and Naidu R.A.S, Transdermal Drug Delivery, 
A Review of Current Status, Indian Drugs, 1995, 32(9), 414-
422. 
4. Divyesh Patel, Nirav Patel, Transdermal Drug Delivery System-
Review, International Journal of Biopharmaceutical and 
Toxicological Research, 2011, 1(1), 61-80. 
5. Yie W,Chien, Novel Drug Delivery Systems, 2nd ed, M. Dekker, 
2005, 50, 301-380. 
6. Eseldin Keleb, Rakesh Kumar Sharma, Transdermal Drug 
Delivery System-Design and Evaluation, International Journal 
of Advances in Pharmaceutical Sciences, 2010, 1(3), 201-211.  
7. Ankush I, Shembale, Useful Permeation Enhancers for 
Transdermal Drug Delivery A Review, IJPRD, 2010, 5, 1-6. 
8. Brian W, Barry, Dermatological Formulations Percutaneous 
Absorption, 18, 95-126. 
9. Hadgraft J.W, and Somers G.F, Review Article Percutaneous 
absorption, International Journal of Pharmaceutics, 2005, 305, 
2-12. 
10. Gilbert S, Banker, Christopher T, Rhodes, Modern 
Pharmaceutics, 2
nd
 Ed, Revised and Expanded, 40, 263-298, 
11. Jain N. K, Controlled and Novel Drug Delivery, 1997, 100-115. 
12. Swarnlata Sonl and Vinod K, Dixit, Transdermal Penetration 
Enhancers, Categorization, Indian Drugs, 1992, 29(11), 465-
471. 
13. Tanu Bhargava, Current trends in NDDS with special reference 
to NSAIDS, International Journal of Pharma and Bio Sciences, 
2011, 2, 92-114.  
14. Lyn Margetts, and  Richard Sawyer, Transdermal Drug 
Delivery: Principles And opioid Therapy, Continuing Education 
in Anaesthesia, Critical Care & Pain, 2007,7(5),171-176. 
15. Nikhil Sharma, Geta Agarwal, Rana A.C, A Review 
Transdermal Drug Delivery System a tool for Novel Drug 
Delivery System,  IJDDR, 2011, 3 (3), 70. 
16. Mohamed Aqil, Yasmin Sultana and Asgar Ali, Matrix Type 
Transdermal Drug Delivery Systems of Metoprolol Tartrate, In- 
vitro Characterization,  Acta Pharm, 2003,53, 119-125. 
17. Basubramanian V, Iyer and Ravindra C, Vasavada, Evaluation 
of Lanolin alcohol flims and Kinetics of Triamcinolone 
Acetonide Release, Journal of Pharmaceutical Sciences, 1979, 
68(6),119-125.  
18. Chowdary K.PR  and Naidu R.A.S, Preparation and Evaluation 
of Cellulose Acetate Films as Rate Controlling Membranes for 
Transdermal use, Indian Drugs, 1991, 29 (7), 312-315. 
19. Mamatha T, Venkateswara Rao J, Mukkanti K,  Development 
of Matrix Type Transdermal Patches of Lercanidipine 
Hydrochloride, Physicochemical and in-vitro 
Characterization, DARU, 2010, 18 (1), 9 -16. 
20. Sridevi S, Chary M.G, Krishna D.R, Prakash V, Diwan, 
Pharmacodynamic Evaluation of Transdermal Drug Delivery 
System of Glibenclamide in Rats, Indian Journal of 
Pharmacology, 2000, 32, 309-312. 
21. Sharma Teja, Rawal Gaurav,  Transdermal Therapeutic 
Systems, An overview,  International Journal of Pharmaceutical 
& Biological Archives, 2011, 2(6),1581-1587. 
22. Wiechers J, Use of Chemical Penetration Enhancers in 
Transdermal Drug Delivery-Possibilities and Difficulties, Acta 
Pharm, 1992, 4, 123. 
23. Manvi F.V, Dandagi P.M, Gadad A.P, Mastiholimat V.S and 
Jagdeesh T, Formulation of Transdermal Drug Delivery System 
of Ketotifen Fumarate, IJPS, 2003, 65(3), 239-243. 
24. Kanikkannan N, Jayaswal S.B and Singh J, Transdermal 
Delivery of Indomethacin: Release Profile of Drug from 
Polymeric Patches, Indian Drugs, 30(9), 441-445. 
25. Sankar V, Velrajan G, Palaniappan R and Rajasekar S, Design 
and Evaluation of Nifedipine Transdermal Patches,  IJPS, 2003, 
65(5), 510-515. 
26. Ryan F, Donnelly, Paul A, McCarron, Design and 
Physicochemical Characterization of a Bioadhesive Patch for 
Dose-Controlled Topical Delivery of Imiquimod, International 
Journal of Pharmaceutics, 2006, 307,318-325. 
27. Hemangi J, Patel, Jitendra S, Patel, Keyur D, Patel, Transdermal 
Patch for Ketotifen Fumarate as Asthmatic Drug,  IJPR, 
2009,l(1),1297-1304. 
28. Shalu Rani, Kamal Saroha, Navneet Syan, Transdermal Patches 
a successful tool in Transdermal Drug Delivery System: An 
overview, Der Pharmacia Sinica, 2011, 2 (5),17-29. 
Prabhakar et al                  Journal of Drug Delivery & Therapeutics; 2013, 3(4), 213-221 214 
© 2011, JDDT. All Rights Reserved                                                      ISSN: 2250-1177                                                     CODEN (USA): JDDTAO 
29. Azhar Ahmed, Nirmal Karki, Rita Charde, Manoj Charde, 
Bhushan Gandhare, Transdermal Drug Delivery Systems, An 
overview, International Journal of Biomedical and Advance 
Research, 2011, 02(01),38-56. 
30. Parthasarathy G, Bhaskar reddy K and Prasanth V.V, 
Formulation and Characterization of Transdermal Patches of 
Naproxen with various polymers,  International Journal of 
Comprehensive Pharmacy , 2011, 6 (07), 1-3. 
31. Kavitha K and More Mangesh Rajendra, Design and Evaluation 
of Transdermal Films of Lornoxicam, IJPBS, 2011, 2(2), 54-62. 
32. Shalu Rani, Kamal Saroha, Navneet Syan, Pooja Mathur, 
Transdermal Patches A Successful Tool In Transdermal Drug 
Delivery System: An overview, Der Pharmacia Sinica, 2011, 2 
(5), 17-29. 
33. Kamal Saroha, Bhavna Yadav, Benika Sharma, Transdermal 
Patch, A Discrete Dosage Form, International Journal of  
Current Pharma Research, 2011,3(3), 98-108. 
34. Shah S, Transdermal Drug Delivery Technology Revisited, 
Recent Advances, Pharmainfo Net, 2008, 6(5),  
35. Prabhu Prabhakara, Marina Koland, Preparation and Evaluation 
of Transdermal Patches of Papaverine Hydrochloride, 
International Journal of Research Pharmaceutical Sciences, 
2010,1(3), 259-266. 
36. Kulkarni V.H, Keshavayya J, Transdermal Delivery of 
Terbutaline sulphate through modified Chitosan membrane, 
Indian Journal of Pharmaceutical Education, 2004, 38(4), 189-
190.  
37. Mutalik, N, Udupa, Glibenclamide Transdermal Patches, 
Physicochemical, Pharmacodynamic and Pharmacokinetic 
Evaluations, Journal of Pharmaceutical Sciences, 2004, 93 (6), 
1557-1594. 
38. Pravin Gavali, Atul, Gaikwad, Radhika P.R, Sivakumar T, 
Design and Development of Hydroxypropyl Methylcellulose 
based polymeric film of Enalapril Maleate, International Journal 
Of Pharmtech Research, 2010, 2(1), 274-282. 
39. Basavaraj K, Nanjwade, Kiran Suryadevara, Kella M.R and Sai 
Susmitha, Formulation and Evaluation of Transdermal Patches 
of Ondansetron Hydrochloride using various polymers in 
different ratios, Current Trends In Biotechnology and 
Pharmacy, 2010, 4 (4), 917-921. 
40. Janos Bajdik, Geza Regdon JR, The effect of the solvent on the 
film-forming parameters of Hydroxypropyl-cellulose, 
International Journal of Pharmaceutics, 2005, 301,  192-198.  
41. Koteshwar K.B, Udupa N and Vasantha Kumar, Design and 
Evaluation of Captopril Transdermal Preparations, Indian 
Drugs, 15 (29), 680-685.  
42. Priyanka Arora, Biswajit Mukherjee, Design Development 
Physicochemical and in-vitro Evaluation of Transdermal 
Patches Containing Diclofenac Diethylammonium Salt, Journal 
of Pharmaceutical Sciences, 2002, 91(9), 2076-2089. 
43. Sankar V, Velrajan G, Palaniappan R and Rajasekar S, Design 
and Evaluation of Nifedipine Transdermal Patches,  Indian 
journal of Pharmaceutical, Sciences, 2003, 65(5), 510-515. 
44. Manvi F.V, Dandagi P.M, Gadad A.P, Mastiholimat V.S and 
Jagdeesh T, Formulation of  Transdermal Drug Delivery  
System of Ketotifen Fumarate, Indian journal of Pharmaceutical 
Sciences, 2003, 65(3), 239-243. 
45. Bharkatiya M, Nema R.K, Bhatnagar M,
 
Designing and 
Characterization of Drug free patches for Transdermal 
Application, IJPSDR 2010, 2(1), 35-39.  
46. Yuveraj Singh Tanwar, Chetan Singh Chauhan, Anshu Sharma, 
Development and Evaluation of Carvidilol Transdermal 
Patches, Acta Pharm, 2007,57, 151–159. 
47. Diveyesh Patel, Nirav Patel, Meghal Parmar, Transdermal Drug 
Delivery System, Review, International Journal of 
Biopharmaceutical and Toxicological Research,2011,1(1),61-
80. 
48. Deepak Gondaliya
 
and Kilambi Pundarikakshudu, Studies in 
Formulation and Pharmacotechnical Evaluation of Controlled 
Release Transdermal Delivery System of Bupropion, AAPS 
Pharmscitech, 2003, 4 (1), 1-9.  
49.  Vamshi Vishnu Y, Chandrasekhar K, Ramesh G and  
Madhusudan Rao Y, Development of Mucoadhesive Patches for 
Buccal Administration of Carvedilol, Current Drug Delivery, 
2007, 4, 27-39. 
50. Amnon C, Sintov, Igor Krymberk, Vladimir Gavrilov and 
Rafael Gorodischer, Transdermal Delivery of Paracetamol for 
Paediatric use, effects of vehicle formulations on the 
percutaneous penetration, Journal of Pharmacy and 
Pharmacology, 2003, 55, 911-919.  
51. Ayman el-kattan, Charles, S, Asbill and sam haidar, transdermal 
testing, practical aspects and methods, PSTT, 2000, 3(12), 426-
430. 
52. Samir D, Roy and Elizabeth Manoukian, Transdermal Delivery 
of ketorolac Tromethamine, Permeation enhancement, Device 
Design, and Pharmacokinetics in Healthy Humans, Journal of 
Pharmaceutical Sciences, 1995, 84 (10), 1190-1199.  
53. Rajeev Gokhale, Cynthia Schmidt, Lisa Alcorn, James 
Stolzenbach, Transdermal Drug Delivery Systems of Albuterol, 
In Vitro and In Vivo Studies, Journal of Pharmaceutical 
Sciences, 1992, 81(10), 996-999.  
54. Deepak Gondaliya and Kilambi Pundarikakshudu, Studies in 
formulation and pharmacotechnical evaluation of Controlled 
Release Transdermal Delivery System of Bupropion, AAPS 
PharmSciTech, 2003, 4(1), 1-9.  
55. Kumar,S,K, Jain,S,K, Pancholi,S,S, Agrawal,S, Saraf,D,K and 
Agrawal,G,P, Provesiculare Transdermal Drug Delivery System 
of Ethinylestradiol and Levonorgestrel for Contraception and 
Hormone Replacement Therapy, Indian journal of Pharm, Sci, 
2003, 65(6), 620-627.  
56. Sadhana P, Gupta and S,K, Jain, Effective and controlled 
Transdermal Delivery of Metoprolol Tartarate, Indian journal of 
Pharmaceutical Sciences, 2005, 67(3), 346-350.  
57. Csoka, E, Csanyi, Eros,I, In-vitro and in- vivo Percutaneous 
absorption of topical dosage forms, case studies, International 
Journal of Pharmaceutics, 2005,291, 11-19.  
58. P,mayorga, F, Puisieux, Couarraze,G, Formulation study of 
Transdermal delivery systems of primaquine, International 
journal of Pharmaceutics, 1996, 132, 71-79.  
59. Mohamed Aqil, Yasmin Sultana Asgar Ali, Matrix Type 
Transdermal Drug Delivery Systems of Metoprolol Tartrate, In 
Vitro Characterization, Acta Pharm, 2003, 53,119–125. 
 
 
 
 
 
 
 
